A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

Autor: Elmira Far, Marco Egbring, Gerd A. Kullak-Ublick, Mathis Brauchbar, Michael Dietrich, Malgorzata Roos, Andreas Trojan
Přispěvatelé: University of Zurich, Trojan, Andreas
Rok vydání: 2016
Předmět:
medicine.medical_specialty
Telemedicine
Activities of daily living
020205 medical informatics
Health Informatics
610 Medicine & health
Breast Neoplasms
02 engineering and technology
Disease
law.invention
03 medical and health sciences
0302 clinical medicine
Breast cancer
breast cancer
Randomized controlled trial
law
Physicians
Surveys and Questionnaires
mobile app
Activities of Daily Living
0202 electrical engineering
electronic engineering
information engineering
Medicine
Humans
030212 general & internal medicine
Adverse effect
2718 Health Informatics
daily functional activity
Original Paper
business.industry
Common Terminology Criteria for Adverse Events
10060 Epidemiology
Biostatistics and Prevention Institute (EBPI)
Middle Aged
medicine.disease
Mobile Applications
collaboration
Clinical trial
10199 Clinic for Clinical Pharmacology and Toxicology
Physical therapy
Female
business
Zdroj: Journal of Medical Internet Research
ISSN: 1438-8871
0200-4496
Popis: Background: The well-being of breast cancer patients and reporting of adverse events require close monitoring. Mobile apps allow continuous recording of disease- and medication-related symptoms in patients undergoing chemotherapy. Objective: The aim of the study was to evaluate the effects of a mobile app on patient-reported daily functional activity in a supervised and unsupervised setting. Methods: We conducted a randomized controlled study of 139 breast cancer patients undergoing chemotherapy. Patient status was self-measured using Eastern Cooperative Oncology Group scoring and Common Terminology Criteria for Adverse Events. Participants were randomly assigned to a control group, an unsupervised group that used a mobile app to record data, or a supervised group that used the app and reviewed data with a physician. Primary outcome variables were change in daily functional activity and symptoms over three outpatient visits. Results: Functional activity scores declined in all groups from the first to second visit. However, from the second to third visit, only the supervised group improved, whereas the others continued to decline. Overall, the supervised group showed no significant difference from the first (median 90.85, IQR 30.67) to third visit (median 84.76, IQR 18.29, P=.72). Both app-using groups reported more distinct adverse events in the app than in the questionnaire (supervised: n=1033 vs n=656; unsupervised: n=852 vs n=823), although the unsupervised group reported more symptoms overall (n=4808) in the app than the supervised group (n=4463). Conclusions: The mobile app was associated with stabilized daily functional activity when used under collaborative review. App-using participants could more frequently report adverse events, and those under supervision made fewer and more precise entries than unsupervised participants. Our findings suggest that patient well-being and awareness of chemotherapy adverse effects can be improved by using a mobile app in collaboration with the treating physician. ClinicalTrial: ClinicalTrials.gov NCT02004496; https://clinicaltrials.gov/ct2/show/NCT02004496 (Archived by WebCite at http://www.webcitation.org/6k68FZHo2) [J Med Internet Res 2016;18(9):e238]
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje